Clinical Efficacy and Mechanism of Modified Erxian Decoction in Treating Osteoporosis with Yang Deficiency
10.13422/j.cnki.syfjx.20192325
- VernacularTitle:加味二仙汤治疗阳虚质骨质疏松症临床疗效及机制
- Author:
Shi-zhou CHEN
1
;
Guo-qing MAO
1
;
Yu-ming SUN
1
;
Lu-mei CAO
1
;
Long-xiu QIN
1
;
Yao YAO
1
;
Jian-feng GE
1
Author Information
1. Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China
- Publication Type:Research Article
- Keywords:
modified Erxian decoction;
osteoporosis;
Yang deficiency;
bone mineral density;
bone metabolism
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2020;26(7):104-108
- CountryChina
- Language:Chinese
-
Abstract:
Objective::To observe the effect of modified Erxian decoction on the physical condition, pain in the lower back and joints, limb activity, bone density, bone metabolism and biochemical indexes in patients with osteoporosis caused by Yang deficiency, in order to explore the possible mechanism. Method::Totally 100 cases of osteoporosis with Yang deficiency were randomly divided into treatment group and control group, with 50 cases in each group. The control group was treated with basic anti-osteoporosis therapy, and the treatment group was give modified Erxian decoction combined with basic therapy for 6 weeks. Short physical performance battery (SPPB) scores of low back and joint pain and Yang deficiency symptom score before and after treatment were recorded and analyzed. before and after treatment, the changes of blood serum calcium (Ca), phosphorus (P), L1-4, femoral neck bone mineral density(BMD), osteocalcin (BGP) and type I collagen peptide amino end level (P1NP) were measured. Result::The scores of lumbar back and joint pain, Yang deficiency symptom score, limb function and activity, lumbar spine 1-4 (L1-4), femoral neck BMD, Ca, P, BGP and P1NP between two groups before treatment had no statistically significant difference. After 6 weeks of treatment, limb activity score, L1-4, femoral neck BMD, serum Ca and P levels in treatment group were significantly higher than those in control group (P<0.05). The scores of the pain in the lower back and joints, Yang deficiency symptom score, BGP and P1NP in treatment group were significantly lower than those in control group (P<0.05). Conclusion::Modified Erxian decoction can significantly alleviate the pain in the lower back and joints of patients with osteoporosis caused by Yang deficiency, enhance the limb function and activity status, improve the physical condition and bone density of patients, reduce bone conversion, with a good effect in treating and alleviating symptoms of osteoporosis caused by Yang deficiency.
